Miromatrix Awarded Federal Supply Schedule Contract for Government Sales

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care, announced today that they have been awarded a Federal Supply Schedule (FSS) contract to sell their product, MIROMESH® in all government facilities (e.g. VA Hospitals, DOD, etc.).  The earning of this contract further accentuates the innovative nature of MIROMESH, as it is the only highly vascularized porcine liver-derived biologic soft tissue reinforcement mesh in the world.  Pending review, MIRODERM®, Miromatrix’ porcine liver-derived biologic wound matrix is expected to be added to the contract in Q2 ’17.